◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2252

Shanghai MicroPort MedBot (Group) Co., Ltd. (2252) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Devices · DATA UPDATED 2026-08-11

Shanghai MicroPort MedBot (Group) Co., Ltd. (2252) operates in the Medical Devices industry and is headquartered in Shanghai, China with about 464 employees. Its market capitalization is roughly CNY 26 billion. In the fiscal year ended 2025-12-31, 2252 reported CNY 551M in revenue and (CNY 250M) in net income.

Shanghai MicroPort MedBot (Group) Co., Ltd. engages in the research and development, manufacturing, and sale of surgical robots in the People's Republic of China.

Interactive charts & full statements →

2252 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 551MCNY 257MCNY 105MCNY 22M
Gross ProfitCNY 267MCNY 86MCNY 15MCNY 7M
Operating Income (EBIT)(CNY 171M)(CNY 474M)(CNY 900M)(CNY 1.1B)
Net Income(CNY 250M)(CNY 642M)(CNY 1.0B)(CNY 1.1B)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2252 Free Cash Flow History

2252 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 1.3BCNY 1.3BCNY 1.4BCNY 1.9B
Total LiabilitiesCNY 935MCNY 1.0BCNY 926MCNY 522M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2252 viewer.

Other Companies in Medical Devices

← 2251All “0-9” companies2255 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.